Mastek Q4FY26 Revenue at ₹938 Crore, Up 3.6% YoY; Proposes ₹16 Dividend
Mastek Limited reported Q4FY26 revenue of ₹938.0 crore, up 3.6% YoY. The 12-month order backlog grew 24.4% YoY to ₹2,849.2 crore. The company proposed a final dividend of ₹16 per share, totaling 480% for FY26. Over 25 AI deals were closed in the quarter.
The results show steady growth and a commitment to shareholder returns, which are positive indicators for investors. However, the growth rates are moderate, and there are no significant new strategic initiatives announced that would drastically alter the company's trajectory.
The company reported year-on-year revenue growth, a significant increase in order backlog, and a proposed dividend increase, indicating positive financial performance and shareholder returns.
Mastek Limited announced its financial results for the fourth quarter and full year of FY26, ending March 31, 2026. The company reported a Q4FY26 revenue of ₹938.0 crore, marking a 3.6% year-on-year increase. The 12-month order backlog grew by 24.4% year-on-year in rupee terms, reaching ₹2,849.2 crore.
The company's UK business continued to drive growth, with a 21.8% increase in INR terms for FY26, primarily fueled by the healthcare sector which saw a 95% year-on-year growth. Mastek also reported closing over 25 AI-assisted deals in the quarter, contributing to a full-year total of 85+ deals.
Deepak Kedia, Chief Financial Officer, highlighted resilient performance with operating EBITDA margins at 16.1% and PAT margins at 11.0%. The company emphasized working capital efficiency, with Days Sales Outstanding (DSO) improving to 73 days and a healthy addition to cash and cash equivalents, resulting in a closing balance of ₹938.5 crore.
Reflecting its commitment to shareholder returns, the Board has recommended a final dividend of ₹16 per share, aggregating to 480% for the year, compared to 460% in FY25. The company also announced the strengthening of its leadership with the appointment of a new Chief Financial Officer and Chief Human Resources Officer.
What to do with a filing like this
Mastek Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mastek Limited. Read the original for the full detail.